Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

128 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-04-11

Study Completion Date

2017-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

NCT04925141

Chronic Myelogenous Leukemia - Chronic Phase

COMPLETED PHASE4

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

NCT00481247

Myeloid Leukemia, Chronic

COMPLETED PHASE3

Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib

NCT02348957

Myeloid Leukemia, Chronic, Chronic-Phase

COMPLETED

Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

NCT00895297

Chronic Myeloid Leukemia

TERMINATED PHASE2

Dasatinib Holiday for Improved Tolerability

NCT02890784

Myeloid Leukemia, Chronic

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breakpoint cluster region (BCR)

Abelson murine leukemia viral oncogene homolog 1 (c-ABL)

Chronic myeloid leukemia (CML)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CML patients treated with dasatinib

Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)

Dasatinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasatinib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sprycel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Because this is a product registry study, it will include adult CML patients in any phase treated with dasatinib in China if they meet the following criteria:

* Willing and able to provide written informed consent
* ≥18 years of age
* Confirmed diagnosis of CML patients by attending physician
* Naive to dasatinib before enrollment in study treatment or have received \<3 months of dasatinib treatment
* Plan to or are receiving dasatinib therapy based on physician's clinical judgment
* Administered dasatinib after imatinib-resistance or intolerance